Business
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB PITTSBURGH, May 18, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that, on May 15, 2026, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing au
About this update from Krystal Biotech, Inc.
[{"type":"image","alt":"Krystal Biotech, Inc.","displaySize":"","headline":null,"caption":"Krystal Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/65807d69171535c646e8328b9e91b8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zsnb4.XQl64tDl7p9EaeHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/65807d69171535c646e8328b9e91b8eb","width":300,"height":56},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Zsnb4.XQl64tDl7p9EaeHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/65807d69171535c646e8328b9e91b8eb","width":300,"height":56}},"lazy":false},{"type":"text","content":"VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan ","length":170,"tagName":"p"},{"type":"text","content":"VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB","length":93,"tagName":"p"},{"type":"text","content":"PITTSBURGH, May 18, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that, on May 15, 2026, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth.","length":454,"tagName":"p"},{"type":"text","content":"VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB and is designed to address the root cause of the disease by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing. The approval in the United Kingdom also includes flexible administration options similar to those granted in the United States, European Union, and Japan, allowing for dosing at home or in a healthcare setting, with the option for administration by patients or their caregivers.","length":588,"tagName":"p"},{"type":"text","content":"“This latest approval brings VYJUVEK closer to patients in the United Kingdom and advances our v...